New breast cancer drug 'slows down progression'
A new breast cancer drug has been shown to slow down the progression of advanced cases of the disease by more than 50%, drug company GlaxoSmithKline said today.
GSK said it had stopped enrolling women on its final phase of clinical trials for oral drug Tykerb after tests revealed it was effective in cases where other drugs, such as Herceptin, had failed.
